Tennessee Center for Clinical Trials | Tullahoma, TN
Status and phase
Conditions
Treatments
About
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 18 to ≤ 85 years
Lp(a)≥ 200 nmol/L during screening
History of ASCVD as evidenced by history of either:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
7,297 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Amgen Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal